BCR–ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy

References

Page 1

	Year	Citations
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy Satu Mustjoki, Marja Ekblom, T. Petteri Arstila, Leukemia MedicineMalignant Blood DisorderImmunologyImmune Checkpoint InhibitorCell Biology	2009	316
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation Andrew E. Schade, Gary L. Schieven, Robert Townsend, Blood	2007	294
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy Anna Kreutzman, Vesa Juvonen, Veli Kairisto, Blood	2010	170
Graft-versus-leukemia effects associated with detectable Wilms tumor-1–specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia Katayoun Rezvani, Agnes S. M. Yong, Bipin N. Savani, Blood	2007	167
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia Dong H. Kim, Suzanne Kamel‐Reid, Hong Chang, Haematologica Hematological MalignancyLymphoid NeoplasiaTherapeutic EffectAutoimmune DiseaseDasatinib Therapy	2008	140
Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia Katayoun Rezvani, Agnes S. M. Yong, Abdul Tawab, Blood	2008	124
The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro Stephen J. Blake, Timothy P. Hughes, Graham Mayrhofer, Clinical Immunology Hematological MalignancyNormal Human T-lymphocytesMalignant Blood DisorderImmunologyHematology	2008	111
Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy Peter Rohoň, Kimmo Porkka, Satu Mustjoki European Journal Of Haematology	2010	89
Development and dynamics of robust T-cell responses to CML under imatinib treatment Christiane I-U. Chen, Holden T. Maecker, Peter P. Lee Blood	2008	83
Emergence of BCR-ABL–specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment Giovanni Riva, Mario Luppi, Patrizia Barozzi, Blood	2009	47

Page 1